CRISPR Therapeutics AG

CRSP · NASDAQ

$49.88−$0.16 (−0.32%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $50.04

About CRSP

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Employees: 393
Headquarters: Zug, Zug
Listed: Oct 19, 2016
Sector: Health Care
Industry: Biotechnology
Website: crisprtx.com

Leadership

CRISPR Therapeutics AG executives
Name	Title	Since	Age
Samarth Kulkarni	—	2017	46
Raju Prasad	—	—	41
James Kasinger	—	—	53
Naimish Patel	—	—	53
Douglas Treco	—	—	67
Briggs Morrison	—	—	66
Ali Behbahani	—	—	48
Maria Fardis	—	—	57
H. Edward Fleming	—	—	62
Simeon George	—	—	48
John Greene	—	—	59
Katherine High	—	—	73
Sandesh Mahatme	—	—	60
Christian Rommel	—	—	58
Susan Kim	—	2018	—

Revenue by product and region

Fiscal year ended Dec 31, 2024: $37.31M total revenue

By product

Collaboration revenue.$35.00M93.8%
Grant [Member]$2.31M6.2%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

CRISPR Therapeutics AG suppliers and customers
Company	Relationship	Country	Correlation
CureVac CVAC	Supplier and customer	DE	0.93
Nkarta NKTX	Supplier and customer	US	0.91
CryoPort CYRX	Supplier	US	0.70
Vertex Pharmaceuticals VRTX	Supplier and customer	US	-0.74
MaxCyte MXCT	Supplier and customer	US	—
KSQ Therapeutics, Inc.	Supplier and customer	US	—
Minapharm Pharmaceuticals MIPH	Supplier and customer	EG	—
University of California	Supplier and customer	US	—
University of Vienna	Supplier and customer	AT	—
Capsida Biotherapeutics, Inc.	Supplier and customer	US	—

Similar companies

Companies in the same industry as CRISPR Therapeutics AG

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.